Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your bladder, kidney, and/or ureter for urothelial cancer (a type of bladder/kidney cancer) within the past 3–16 weeks.
- Your cancer was at high risk of coming back, based on the stage found after surgery and whether you had chemotherapy before surgery.
- You have a blood test result (Signatera) that shows whether tumor DNA is present in your blood, or you are willing to have this test done.
- You are generally healthy enough for daily activities (ECOG score 0–2) and your kidney, liver, and blood counts are within acceptable ranges.
- You do not have an active autoimmune disease or history of certain immune-related side effects that would make immunotherapy unsafe.
- You have not had other cancer treatments (like radiation or chemotherapy) after surgery, and you are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
This trial tests a combination of three drugs before bladder removal surgery in people with muscle-invasive bladder cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.